The new food and drug administration drug package insert: Implications for patient safety and clinical care

Anesthesia and Analgesia

Volumn 108, Issue 1, 2009, Pages 211-218

  Watson, Kelley Teed ^a   Barash, Paul G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTACID AGENT; ANTITHROMBOCYTIC AGENT; CHOLINASOL; CIMETIDINE; DIGOXIN; IMDICON; ISOPRENALINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENAZONE; PHENOBARBITAL; PHENYTOIN; PROPRANOLOL DERIVATIVE; SULFANILAMIDE; THEOPHYLLINE; UNCLASSIFIED DRUG;

AGRANULOCYTOSIS; APLASTIC ANEMIA; BLEEDING; CLINICAL FEATURE; CLINICAL PRACTICE; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG FATALITY; DRUG INFORMATION; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG PACKAGING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEVER; FOOD; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL PAIN; HEALTH CARE COST; HUMAN; INCIDENCE; INFECTION; INHALER; INTERNET; JAUNDICE; MEDICAL SOCIETY; MEDICATION ERROR; NAUSEA; NEUTROPENIA; PALLOR; PATIENT CARE; PATIENT SAFETY; PETECHIA; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; REVIEW; STROKE; THROMBOCYTOPENIC PURPURA; THROMBOSIS; TREATMENT FAILURE; WEAKNESS; ARTICLE; DRUG TOXICITY; GOVERNMENT REGULATION; HISTORY; LEGAL ASPECT; PRACTICE GUIDELINE; SAFETY; UNITED STATES;

CONSUMER PRODUCT SAFETY; DRUG APPROVAL; DRUG INFORMATION SERVICES; DRUG LABELING; DRUG TOXICITY; GOVERNMENT REGULATION; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERNET; MEDICATION ERRORS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 58749086751     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ane.0b013e31818c1b27     Document Type: Article

References (35)

1. Kurian GT, Harahan JP. A historical guide to the U.S. government. New York: Oxford University Press, 1998
2. Wax PM. Elixirs, diluents, and the passage of the 1938 federal food, drug and cosmetic act. Ann Intern Med 1995;122:456-61
3. Schultz WB. Bolstering the FDA's drug-safety authority. N Engl J Med 2007;357:2217-9
4. Aspden P. Institute of Medicine. Committee on identifying and preventing medication errors. Preventing medication errors. Washington, DC: National Academies Press, 2007
5. National Biosystems I. Focus Group Report: physician's perceptions of prescription drug labeling information. Focus Group. Plymouth, MN: National Biosystems, Incorporated, 1992. Report No. Contract #223-91-3501
6. Chang NS, Simone AF, Schultheis LW. From the FDA: what's in a label? A guide for the anesthesia practitioner. Anesthesiology 2005;103:179-85
7. LittleJohn JK. Package insert: view of a rural town practitioner. Drug Inf J 1987;21:63-5
8. Avorn J. FDA standard: good enough for government work? N Engl J Med 2005;353:969-72
9. Action plan for the provision of useful prescription med information. Available at: http://www.keystone.org/spp/documents/ FinalActionplan.pdf. Accessed March 5, 2008
10. CIOMS Working Group III. Guidelines for preparing core clinical-safety information on drugs. Guidelines. Geneva, Switzerland: Council for International Organizations of Medical Sciences, 1995
11. Requirements on content and format of labeling for human prescription drug and biological products. 21 CFR § 201, 314, and 601
12. Avorn J, Shrank W. Highlights and a hidden hazard-the FDA's new labeling regulations. N Engl J Med 2006;354:2409-11
13. Institute of Medicine (U.S.). Committee on the assessment of the US drug safety system. The future of drug safety: promoting and protecting the health of the public. Baciu A, Stratton KR, Burke SP, eds. Washington, DC: National Academies Press, 2007
14. Center for Drug Evaluation and Research. Warnings and precautions, contraindications, and boxed warning sections of labeling for human prescription drug and biological products-content and format. Guidance for Industry. Rockville, MD: U.S. Department of Health and Human Services, 2006
15. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA 2007;297:308-11
16. Beach JE, Faich GA, Bormel FG, Sasinowski FJ. Black box warnings in prescription drug labeling: results of a survey of 206 drugs. Food Drug Law J 1998;53:403-11
17. Liang BA. FDA use of the black box warning: time for reevaluation as a safety tool. J Clin Anesth 2002;14:561-3
18. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron. Anesthesiology 2005;102:1094-100
19. Charbit B, Funck-Brentano C. Droperidol-induced proarrhythmia: the beginning of an answer? Anesthesiology 2007; 107:524-6
20. Nuttall GA, Eckerman KM, Jacob KA, Pawlaski EM, Wigersma SK, Marienau ME, Oliver WC, Narr BJ, Ackerman MJ. Does low-dose droperidol administration increase the risk of druginduced QT prolongation and torsade de pointes in the general surgical population? Anesthesiology 2007;107:531-6
21. White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose droperidol on the QT interval during and after general anesthesia: a placebo-controlled study. Anesthesiology 2005; 102:1101-5
22. Wagner AK, Chan KA, Dashevsky I, Raebel MA, Andrade SE, Lafata JE, Davis RL, Gurwitz JH, Soumerai SB, Platt R. FDA drug prescribing warnings: is the black box half empty or half full? Pharmacoepidemiol Drug Saf 2006;15:369-86
23. Uhl K, Kennedy DL, Kweder SL. Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs. Drug Saf 2002;25:885-92
24. Center for Drug Evaluation and Research. Adverse reactions section of labeling for human prescription drug and biological products-content and format. Guidance for Industry. Rockville, MD: U.S. Department of Health and Human Services, 2006
25. Silver NC, Braun CC. Perceived readability of warning labels with varied font sizes and styles. Saf Sci 1993;16:615-25
26. FDA proposes rules for dissemination information on off-label uses. Available at: www.fda.gov/bbs/topics/NEWS/NEW00643. html. Accessed March 5, 2008
27. O'Reilly J, Dalal A. Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs. Ann Health Law 2003;12:295-324
28. Sorrel AL. Off-label probes are looking into physicians' role. Amednews Com [serial online], 2006. Available at: http://www.ama-assn.org/amednews/2006/ 08/21/gvsb0821.htm. Accessed March 5, 2008
29. The FDA's reputation with the general public is under assault. Available at: http://harrisinteractive.com/news/allnewsbydate. asp?NewsID-1060. Accessed March 5, 2008
30. Lenzer J. Scandals have eroded US public's confidence in drug industry. BMJ 2004;329:247
31. The future of drug safety: promoting and protecting the health of the public, FDA's response to the Institute of Medicine's 2006 report. Available at: http://www.fda.gov/oc/reports/iom013007. html. Accessed March 5, 2008
32. Psaty BM, Charo RA. FDA responds to Institute of Medicine drug safety recommendations-in part. JAMA 2007;297:1917-20
33. The Sentinel Initiative: National strategy for monitoring medical product safety. Rockville, MD: U.S. Department of Health and Human Services, Office of Critical Path Programs, 2008
34. Strom BL. How the US drug safety system should be changed. JAMA 2006;295:2072-5
35. Imdicon. Available at: www.fda.gov/cder/regulatory/physLabel/ Imdicon.pdf. Accessed March, 5, 2008